Research Article
PDF EndNote BibTex RIS Cite

Comparison of tolterodine, trospium chloride, solifenacin treatments and its side effects on patients with pure urinary and mixed incontinence

Year 2022, Volume 5, Issue 5, 1207 - 1214, 25.09.2022
https://doi.org/10.32322/jhsm.1106031

Abstract

Objective: Urinary incontinence is defined as urinary incontinence that is a social or hygienic problem and can be objectively demonstrated. It is aimed to compare tolterodine, trospium chloride and solifenacin treatments, and its side effects on patients who have complaints of pure urinary and mixed incontinence. Material and Method: Totally 98 patients, who applied to Ankara Etlik Zubeyde Hanım Gynecology Training and Research Hospital, Urogynecology Outpatient Clinic between November 2009 and October 2010 with compliants of urinary incontinence and met the criteria to participate in the research, have been included in this study. Results: A significant improvement in each three of the drug group at third and six months was determined. Solifenacin is generally more effective than the other two treatments. When total values of UDI-6 (Urinary Distress Inventory) survey is analysed, it is seen that each of three antimuscarinic drug group ensured improvement on symptoms at the end of the third month as not to be different from the improvement at the six month. Each three antimuscarinic drug group has a significant therapeutic effect on the IIQ-7 (Incontinence Impact Questionnaire) survey which questions the life quality. Whereas complaints of constipation was seen more at patients that use tolterodine and trospium chloride, there was not a significant difference despite a slight increase in the solifenacin group (p>0.05). It is determined that solifenacin caused desert mouth less than the other two drug groups Conclusion: Tolterodine, trospium chloride and solifenacin as anticholinergic drugs meaningfully reduced the activity of bladder and increased the quality of life. Drug therapy provided an effective and efficient improvement on incontinence.

References

  • Abrams P, Blaivas JG, Stanton SL, et al. The standardisation of terminology of lower urinary tract function. Scand J Urol Nephrol 1988; 114: 5–18.
  • Imamura M, Abrams P, Bain C, et al. Systematic review and economic modelling of the effectiveness and cost-effectiveness of non-surgical treatments for women with stress urinary incontinence. Health Technol Assess 2010; 14: 1-188.
  • Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein A. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalance study. Br J Urol Int 2001; 87: 760-6.
  • Stewart WF, Corey R, Herzog AR, et al. Prevalance overactive bladder in women: results from the Noble Program. Int Urogynecol J Pelvic Floor Dysfunct 2001; 12: 66.
  • Mills IW, Greenland JE, McMurray G, et al. Studies of the pathophysiology of idiopathic detrusor instability: the physiological properties of the detrusor smooth muscle and its pattern of innervation. J Urol 2000; 163: 646–51.
  • Ghoniem GM, Walters F, Levis V. The value of vaginal pack test in large cyctoceles. J Urol 1994; 152: 931-4.
  • Wall LL. Diagnosis and management of urinary incontinence due to detrusor instability. Obstet Gynecol Surv 1990; 45: 1–47.
  • Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the stadardisation sub-comittee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78.
  • Michel MC, de la Rosette JJ, Piro M, et al. Comparison of symtom severity and treatment response in patients with incontinent and overactive bladder. Eur Urol 2005; 48: 110-5.
  • Herbison P, Hay Smith J, Ellis G, Moore K. Effectiveness of anticholinerjic drugs compared with placebo in the treatment of overactive bladder: systematic review. Br Med J 2003; 326: 841-4.
  • Scheife R, Pharm D, FCCP; Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Therap 2005; 27: 144-53.
  • Michel MC, Oelke M, Zinner N. Novel muscarinic antagonists to treat incontinence and overactive. Drug Discovery Today 2005: 1-6
  • Kristen Hesch. Agents for treatment of overactive bladder: a therapeutic class review. Proc (Bayl Univ Med Cent) 2007; 20: 307-14.
  • Hay-Smith J, Herbison P, Ellis G, Moore K. Anticholinerjic drugs versus plasebo for overactve bladder syndrome in adults. Cochrane Database Syst Rew 2002: 3.
  • Chapple CR, Arano P, Bosch JL, et al. Solifenacin appears effective and well tolerated in patients with symtomatic idiopathic detrusor overactive in a plasebo and tolterodine controlled phase 2 dose-finding study. BJU Int 2004; 93: 71-7.
  • Haeusler G, Letitch H, Van Trotsenberg M, et al. Drug therapy of urinary urge incontinence. Obstet Gynecol 2002; 100: 1003-16.
  • Drutz H, Appell RA, Gleason D, Klimberg I, Randomski S. Clinical efficacy and safety of tolterodine compared to oxybutynin and plasebo in patients with overactive bladder. Int urogynecol J Pelvic Floor Dysfunc 1999; 10: 283-9.
  • Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new muscarinic agent: as effective but better than oxybutynin and plasebo in patients with an overactive bladder. Br J Urol 1998; 81: 801-10.
  • Anderson KE, Appell R, Cardozo LD, et al. The pharmacological treatment of urinary incontinence. BJU Int 1999; 84: 923-47.
  • Van Kerrebroeck PEVA, Serment G, Dreher E. Clinical efficacy and safety of olterodine compared to oxybutynin in patients with overactive bladder. Neurourol Urodyn 1997; 16: 478-9.
  • Burgio K, Matthews KA, Engel BT. Prevalence, incidence and correlates of urinary incontinence in healthy, middle-aged women. J Urol 1991; 146: 1255-9.
  • Diokno AC, Brock BM, Brown MB et al. Prevelance of urınery incontinance and other urological symtoms in the noninstituinalized elderly. J Urol 1986; 136: 1022-6.
  • Dwyer PL, Lee ETC, Hay DM. Obesity and urinary incontinence in women. Br J Obstet Gynecol 1988; 95: 91-4.
  • Bump RC, Sugarman HJ, Fanti JA, McCiish DK. Obesity and lower urinary tract function in women. Efect of surgically induced vveight loss. Am J Obstet Gynecol 2002; 167: 392-7.
  • Parazzini F, Colli E, Origgi G, et al. Risk factors for urinary incontinence in women. Eur Urol 2000; 37: 637-43.
  • Cam C, Sakalli M, Ay P, Cam M, Karateke A. Validation of the short forms of the incontinence impact questionnaire (IIQ-7) and the urogenital distress inventory (UDI-6) in a Turkish population. Neurourology and Urodynamics 2007; 26: 129-33.
  • Abrams P, Swift S. Solifenasin is Effective for the treatment of OAB dry patients: a pooled analysis. Eur Urol 2005; 48: 483-7.
  • Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005; 464-70.
  • Chapple CR, Fianu Jonsson A, Indig M, et al. STAR study group Treatment outcomes in the STAR study: a subanalysis of 5mg and tolterodine ER 4mg. Eur Urol 2007; 52: 1195-203.
  • Herbison P, Hay Smith J, Ellis G, Moore K. Effectiveness of anticholinerjic drugs compared with plasebo in the treatment of overactive bladder: systematic review. Br Med J 2003; 326: 841-4.
  • Lauti M, Hay-Smith J, Herbison P, et al. Anticholinergic drugs, bladder retraining and their combination for urge urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19: 1533-43.
  • Rovner ES. Trospium chloride in the management of overactive bladder. Drugs 2004; 64: 2433-46.
  • Hesch K. Agents for treatment of overactive bladder: a therapeutic class review. Bayl Univ Med Cent Proceedings 2007; 20: 307-14.
  • Herbison P, Hay Smith J, Ellis G, Moore K. Effectiveness of anticholinerjic drugs compared with plasebo in the treatment of overactive bladder: systematic review. Br Med J 2003; 326: 841-4.
  • Metello J, Nogueira B, Torgal M, et al. Comparison of the efficacy and tolerability of solifenacin succinate with or without previous use of trospium chloride. Int Urogynecol J 2007; 18: 1021-5.
  • Kessler TM, Bachmann LM, Minder C, et al. Adverse event assessment of antimuscarinics for treating overactive bladder. PloS One 2011; 6: 167-8.

Year 2022, Volume 5, Issue 5, 1207 - 1214, 25.09.2022
https://doi.org/10.32322/jhsm.1106031

Abstract

References

  • Abrams P, Blaivas JG, Stanton SL, et al. The standardisation of terminology of lower urinary tract function. Scand J Urol Nephrol 1988; 114: 5–18.
  • Imamura M, Abrams P, Bain C, et al. Systematic review and economic modelling of the effectiveness and cost-effectiveness of non-surgical treatments for women with stress urinary incontinence. Health Technol Assess 2010; 14: 1-188.
  • Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein A. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalance study. Br J Urol Int 2001; 87: 760-6.
  • Stewart WF, Corey R, Herzog AR, et al. Prevalance overactive bladder in women: results from the Noble Program. Int Urogynecol J Pelvic Floor Dysfunct 2001; 12: 66.
  • Mills IW, Greenland JE, McMurray G, et al. Studies of the pathophysiology of idiopathic detrusor instability: the physiological properties of the detrusor smooth muscle and its pattern of innervation. J Urol 2000; 163: 646–51.
  • Ghoniem GM, Walters F, Levis V. The value of vaginal pack test in large cyctoceles. J Urol 1994; 152: 931-4.
  • Wall LL. Diagnosis and management of urinary incontinence due to detrusor instability. Obstet Gynecol Surv 1990; 45: 1–47.
  • Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the stadardisation sub-comittee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78.
  • Michel MC, de la Rosette JJ, Piro M, et al. Comparison of symtom severity and treatment response in patients with incontinent and overactive bladder. Eur Urol 2005; 48: 110-5.
  • Herbison P, Hay Smith J, Ellis G, Moore K. Effectiveness of anticholinerjic drugs compared with placebo in the treatment of overactive bladder: systematic review. Br Med J 2003; 326: 841-4.
  • Scheife R, Pharm D, FCCP; Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Therap 2005; 27: 144-53.
  • Michel MC, Oelke M, Zinner N. Novel muscarinic antagonists to treat incontinence and overactive. Drug Discovery Today 2005: 1-6
  • Kristen Hesch. Agents for treatment of overactive bladder: a therapeutic class review. Proc (Bayl Univ Med Cent) 2007; 20: 307-14.
  • Hay-Smith J, Herbison P, Ellis G, Moore K. Anticholinerjic drugs versus plasebo for overactve bladder syndrome in adults. Cochrane Database Syst Rew 2002: 3.
  • Chapple CR, Arano P, Bosch JL, et al. Solifenacin appears effective and well tolerated in patients with symtomatic idiopathic detrusor overactive in a plasebo and tolterodine controlled phase 2 dose-finding study. BJU Int 2004; 93: 71-7.
  • Haeusler G, Letitch H, Van Trotsenberg M, et al. Drug therapy of urinary urge incontinence. Obstet Gynecol 2002; 100: 1003-16.
  • Drutz H, Appell RA, Gleason D, Klimberg I, Randomski S. Clinical efficacy and safety of tolterodine compared to oxybutynin and plasebo in patients with overactive bladder. Int urogynecol J Pelvic Floor Dysfunc 1999; 10: 283-9.
  • Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new muscarinic agent: as effective but better than oxybutynin and plasebo in patients with an overactive bladder. Br J Urol 1998; 81: 801-10.
  • Anderson KE, Appell R, Cardozo LD, et al. The pharmacological treatment of urinary incontinence. BJU Int 1999; 84: 923-47.
  • Van Kerrebroeck PEVA, Serment G, Dreher E. Clinical efficacy and safety of olterodine compared to oxybutynin in patients with overactive bladder. Neurourol Urodyn 1997; 16: 478-9.
  • Burgio K, Matthews KA, Engel BT. Prevalence, incidence and correlates of urinary incontinence in healthy, middle-aged women. J Urol 1991; 146: 1255-9.
  • Diokno AC, Brock BM, Brown MB et al. Prevelance of urınery incontinance and other urological symtoms in the noninstituinalized elderly. J Urol 1986; 136: 1022-6.
  • Dwyer PL, Lee ETC, Hay DM. Obesity and urinary incontinence in women. Br J Obstet Gynecol 1988; 95: 91-4.
  • Bump RC, Sugarman HJ, Fanti JA, McCiish DK. Obesity and lower urinary tract function in women. Efect of surgically induced vveight loss. Am J Obstet Gynecol 2002; 167: 392-7.
  • Parazzini F, Colli E, Origgi G, et al. Risk factors for urinary incontinence in women. Eur Urol 2000; 37: 637-43.
  • Cam C, Sakalli M, Ay P, Cam M, Karateke A. Validation of the short forms of the incontinence impact questionnaire (IIQ-7) and the urogenital distress inventory (UDI-6) in a Turkish population. Neurourology and Urodynamics 2007; 26: 129-33.
  • Abrams P, Swift S. Solifenasin is Effective for the treatment of OAB dry patients: a pooled analysis. Eur Urol 2005; 48: 483-7.
  • Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005; 464-70.
  • Chapple CR, Fianu Jonsson A, Indig M, et al. STAR study group Treatment outcomes in the STAR study: a subanalysis of 5mg and tolterodine ER 4mg. Eur Urol 2007; 52: 1195-203.
  • Herbison P, Hay Smith J, Ellis G, Moore K. Effectiveness of anticholinerjic drugs compared with plasebo in the treatment of overactive bladder: systematic review. Br Med J 2003; 326: 841-4.
  • Lauti M, Hay-Smith J, Herbison P, et al. Anticholinergic drugs, bladder retraining and their combination for urge urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19: 1533-43.
  • Rovner ES. Trospium chloride in the management of overactive bladder. Drugs 2004; 64: 2433-46.
  • Hesch K. Agents for treatment of overactive bladder: a therapeutic class review. Bayl Univ Med Cent Proceedings 2007; 20: 307-14.
  • Herbison P, Hay Smith J, Ellis G, Moore K. Effectiveness of anticholinerjic drugs compared with plasebo in the treatment of overactive bladder: systematic review. Br Med J 2003; 326: 841-4.
  • Metello J, Nogueira B, Torgal M, et al. Comparison of the efficacy and tolerability of solifenacin succinate with or without previous use of trospium chloride. Int Urogynecol J 2007; 18: 1021-5.
  • Kessler TM, Bachmann LM, Minder C, et al. Adverse event assessment of antimuscarinics for treating overactive bladder. PloS One 2011; 6: 167-8.

Details

Primary Language English
Subjects Health Care Sciences and Services
Journal Section Original Article
Authors

İzzet ÖZGÜRLÜK> (Primary Author)
SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, ANKARA ŞEHİR SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ
0000-0002-9553-9265
Türkiye


Eylem ÜNLÜBİLGİN>
University of Health Sciences, Ankara Etlik Zübeyde Hanım Gynecology Training and Research Hospital, Department of gynecology and obstetrics, Ankara, Turkey
0000-0002-1529-2523
Türkiye


İsmail DÖLEN>
University of Health Sciences, Ankara Etlik Zübeyde Hanım Gynecology Training and Research Hospital, Department of gynecology and obstetrics, Ankara, Turkey
0000-0001-6317-5447
Türkiye

Publication Date September 25, 2022
Published in Issue Year 2022, Volume 5, Issue 5

Cite

Bibtex @research article { jhsm1106031, journal = {Journal of Health Sciences and Medicine}, eissn = {2636-8579}, address = {Kırıkkale Üniversitesi Tıp Fakültesi / İç Hastalıkları Anabilim Dalı}, publisher = {MediHealth Academy Yayıncılık}, year = {2022}, volume = {5}, number = {5}, pages = {1207 - 1214}, doi = {10.32322/jhsm.1106031}, title = {Comparison of tolterodine, trospium chloride, solifenacin treatments and its side effects on patients with pure urinary and mixed incontinence}, key = {cite}, author = {Özgürlük, İzzet and Ünlübilgin, Eylem and Dölen, İsmail} }
APA Özgürlük, İ. , Ünlübilgin, E. & Dölen, İ. (2022). Comparison of tolterodine, trospium chloride, solifenacin treatments and its side effects on patients with pure urinary and mixed incontinence . Journal of Health Sciences and Medicine , 5 (5) , 1207-1214 . DOI: 10.32322/jhsm.1106031
MLA Özgürlük, İ. , Ünlübilgin, E. , Dölen, İ. "Comparison of tolterodine, trospium chloride, solifenacin treatments and its side effects on patients with pure urinary and mixed incontinence" . Journal of Health Sciences and Medicine 5 (2022 ): 1207-1214 <https://dergipark.org.tr/en/pub/jhsm/issue/72677/1106031>
Chicago Özgürlük, İ. , Ünlübilgin, E. , Dölen, İ. "Comparison of tolterodine, trospium chloride, solifenacin treatments and its side effects on patients with pure urinary and mixed incontinence". Journal of Health Sciences and Medicine 5 (2022 ): 1207-1214
RIS TY - JOUR T1 - Comparison of tolterodine, trospium chloride, solifenacin treatments and its side effects on patients with pure urinary and mixed incontinence AU - İzzetÖzgürlük, EylemÜnlübilgin, İsmailDölen Y1 - 2022 PY - 2022 N1 - doi: 10.32322/jhsm.1106031 DO - 10.32322/jhsm.1106031 T2 - Journal of Health Sciences and Medicine JF - Journal JO - JOR SP - 1207 EP - 1214 VL - 5 IS - 5 SN - -2636-8579 M3 - doi: 10.32322/jhsm.1106031 UR - https://doi.org/10.32322/jhsm.1106031 Y2 - 2022 ER -
EndNote %0 Journal of Health Sciences and Medicine Comparison of tolterodine, trospium chloride, solifenacin treatments and its side effects on patients with pure urinary and mixed incontinence %A İzzet Özgürlük , Eylem Ünlübilgin , İsmail Dölen %T Comparison of tolterodine, trospium chloride, solifenacin treatments and its side effects on patients with pure urinary and mixed incontinence %D 2022 %J Journal of Health Sciences and Medicine %P -2636-8579 %V 5 %N 5 %R doi: 10.32322/jhsm.1106031 %U 10.32322/jhsm.1106031
ISNAD Özgürlük, İzzet , Ünlübilgin, Eylem , Dölen, İsmail . "Comparison of tolterodine, trospium chloride, solifenacin treatments and its side effects on patients with pure urinary and mixed incontinence". Journal of Health Sciences and Medicine 5 / 5 (September 2022): 1207-1214 . https://doi.org/10.32322/jhsm.1106031
AMA Özgürlük İ. , Ünlübilgin E. , Dölen İ. Comparison of tolterodine, trospium chloride, solifenacin treatments and its side effects on patients with pure urinary and mixed incontinence. J Health Sci Med / JHSM. 2022; 5(5): 1207-1214.
Vancouver Özgürlük İ. , Ünlübilgin E. , Dölen İ. Comparison of tolterodine, trospium chloride, solifenacin treatments and its side effects on patients with pure urinary and mixed incontinence. Journal of Health Sciences and Medicine. 2022; 5(5): 1207-1214.
IEEE İ. Özgürlük , E. Ünlübilgin and İ. Dölen , "Comparison of tolterodine, trospium chloride, solifenacin treatments and its side effects on patients with pure urinary and mixed incontinence", Journal of Health Sciences and Medicine, vol. 5, no. 5, pp. 1207-1214, Sep. 2022, doi:10.32322/jhsm.1106031

Interuniversity Board (UAK) Equivalency: Ulakbim TR Dizin and 1b [Original research article published in journals scanned by international field indexes (included in indices other than the ones mentioned in 1a) - 10 POINTS]. The Directories (indexes) and Platforms we are included in are at the bottom of the page.

Note: Our journal is not WOS indexed and therefore is not classified as Q.

You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser. https://dergipark.org.tr/tr/journal/2316/file/4905/show







The indexes of the journal are ULAKBİM TR Dizin, Index Copernicus, ICI World of Journals, DOAJ, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, WorldCat (OCLC), MIAR, EuroPub, OpenAIRE, Türkiye Citation Index, Türk Medline Index, InfoBase Index, Scilit, etc.

       images?q=tbn:ANd9GcRB9r6zRLDl0Pz7om2DQkiTQXqDtuq64Eb1Qg&usqp=CAU

500px-WorldCat_logo.svg.png

atifdizini.png

logo_world_of_journals_no_margin.png

images?q=tbn%3AANd9GcTNpvUjQ4Ffc6uQBqMQrqYMR53c7bRqD9rohCINkko0Y1a_hPSn&usqp=CAU

doaj.png  

images?q=tbn:ANd9GcSpOQFsFv3RdX0lIQJC3SwkFIA-CceHin_ujli_JrqBy3A32A_Tx_oMoIZn96EcrpLwTQg&usqp=CAU

ici2.png

asos-index.png

drji.png





The platforms of the journal are Google Scholar, CrossRef (DOI), ResearchBib, Open Access, COPE, ICMJE, NCBI, ORCID, Creative Commons, etc.

COPE-logo-300x199.jpgimages?q=tbn:ANd9GcQR6_qdgvxMP9owgnYzJ1M6CS_XzR_d7orTjA&usqp=CAU

icmje_1_orig.png

cc.logo.large.png

ncbi.pngimages?q=tbn:ANd9GcRBcJw8ia8S9TI4Fun5vj3HPzEcEKIvF_jtnw&usqp=CAU

ORCID_logo.png

1*mvsP194Golg0Dmo2rjJ-oQ.jpeg


Our Journal using the DergiPark system indexed are;

Ulakbim TR Dizin,  Index Copernicus, ICI World of JournalsDirectory of Research Journals Indexing (DRJI), General Impact FactorASOS Index, OpenAIRE, MIAR,  EuroPub, WorldCat (OCLC)DOAJ,  Türkiye Citation Index, Türk Medline Index, InfoBase Index


Our Journal using the DergiPark system platforms are;

Google, Google Scholar, CrossRef (DOI), ResearchBib, ICJME, COPE, NCBI, ORCID, Creative Commons, Open Access, and etc.


Journal articles are evaluated as "Double-Blind Peer Review". 

Our journal has adopted the Open Access Policy and articles in JHSM are Open Access and fully comply with Open Access instructions. All articles in the system can be accessed and read without a journal user.  https//dergipark.org.tr/tr/pub/jhsm/page/9535

Journal charge policy   https://dergipark.org.tr/tr/pub/jhsm/page/10912


Editor List for 2022

Assoc. Prof. Alpaslan TANOĞLU (MD)  

Prof. Aydın ÇİFCİ (MD)

Prof. İbrahim Celalaettin HAZNEDAROĞLU (MD)

Prof. Murat KEKİLLİ (MD)

Prof. Yavuz BEYAZIT (MD) 

Prof. Ekrem ÜNAL (MD)

Prof. Ahmet EKEN (MD)

Assoc. Prof. Ercan YUVANÇ (MD)

Assoc. Prof. Bekir UÇAN (MD) 

Assoc. Prof. Mehmet Sinan DAL (MD)


Our journal has been indexed in DOAJ as of May 18, 2020.

Our journal has been indexed in TR-Dizin as of March 12, 2021.


17873

Articles published in the Journal of Health Sciences and Medicine have open access and are licensed under the Creative Commons CC BY-NC-ND 4.0 International License.